Zhao Guo-Sheng, Zhang Qiao, Cao Ya, Wang Yang, Lv Yang-Fan, Zhang Zhao-Si, Zhang Yuan, Tan Qiu-Lin, Chang Yu, Quan Zheng-Xue, Jiang Dian-Ming, Guo Qiao-Nan
Department of Orthopedic Surgery, The First Affiliated Hospital of Chongqing Medical University Chongqing 400016, People's Republic of China.
Bone and Trauma Center, The Third Affiliated Hospital of Chongqing Medical University Chongqing 401120, People's Republic of China.
Am J Transl Res. 2019 Apr 15;11(4):2117-2139. eCollection 2019.
A lack of understanding of the molecular basis underlying the regulation of metastatic disease and its effective therapy are the primary causes of high mortality in osteosarcoma. Thus, new insights into metastases and novel effective targets for metastatic osteosarcoma are urgently required. Anoikis resistance is considered a hallmark of cancer cells with metastatic ability. However, the molecular mechanism of anoikis is poorly understood in osteosarcoma. We applied immunohistochemistry to investigate the correlation between inhibitor of differentiation or DNA binding 1 (ID1) and clinicopathological features, and investigated the correlation between ID1 and the metastatic behavior of osteosarcoma cells, in vitro and in vivo. The results revealed that ID1 is overexpressed in human osteosarcoma tissues, is positively associated with lung metastases, and is a potential biomarker of poor prognosis. Overexpression of ID1 could increase anoikis insensitivity of osteosarcoma cells to facilitate metastasis through the PI3K/AKT-dependent mitochondrial apoptosis pathway. Knockdown of ID1 partly reversed the high potential of metastasis in anoikis-resistant osteosarcoma cells. Our findings revealed, that ID1 is a candidate molecular target for metastatic potential osteosarcoma by highlighting the role of anoikis resistance. In addition ID1 might be a potential predictor of poor prognosis in patients with osteosarcoma.
对骨肉瘤转移疾病调控的分子基础缺乏了解及其有效治疗方法的缺失是骨肉瘤高死亡率的主要原因。因此,迫切需要对骨肉瘤转移有新的见解以及新的有效治疗靶点。失巢凋亡抗性被认为是具有转移能力的癌细胞的一个标志。然而,在骨肉瘤中对失巢凋亡的分子机制了解甚少。我们应用免疫组织化学来研究分化抑制因子或DNA结合蛋白1(ID1)与临床病理特征之间的相关性,并在体外和体内研究ID1与骨肉瘤细胞转移行为之间的相关性。结果显示,ID1在人骨肉瘤组织中过表达,与肺转移呈正相关,并且是预后不良的一个潜在生物标志物。ID1的过表达可增加骨肉瘤细胞对失巢凋亡的不敏感性,通过PI3K/AKT依赖的线粒体凋亡途径促进转移。敲低ID1可部分逆转失巢凋亡抗性骨肉瘤细胞的高转移潜能。我们的研究结果表明,通过突出失巢凋亡抗性的作用,ID1是骨肉瘤转移潜能的一个候选分子靶点。此外,ID1可能是骨肉瘤患者预后不良的一个潜在预测指标。